id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-D-0575-0045,FDA,FDA-2013-D-0575,Guidance for Industry; Expedited Programs for Serious Conditions – Drugs and Biologics - Final Guidance,Other,Guidance,2023-12-01T05:00:00Z,2023,12,2023-12-01T05:00:00Z,,2026-01-03T12:40:21Z,,1,0,09000064862bd2eb
FDA-2013-D-0575-0044,FDA,FDA-2013-D-0575,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals,Notice,Notice of Approval,2021-05-19T04:00:00Z,2021,5,2021-05-19T04:00:00Z,,2021-05-19T14:50:03Z,2021-10535,0,0,0900006484b1b4dc
FDA-2013-D-0575-0042,FDA,FDA-2013-D-0575,"Agency Information Collection Activities; Submission for Office of Management and Budget Review;
Comment Request; Expedited Programs for Serious Conditions — Drugs and Biologics",Notice,30 Day Proposed Information Collection,2021-02-18T05:00:00Z,2021,2,2021-02-18T05:00:00Z,2021-03-23T03:59:59Z,2021-02-18T15:19:49Z,2021-03244,0,0,0900006484a3c6c3
FDA-2013-D-0575-0040,FDA,FDA-2013-D-0575,Agency Information Collection Activities; Proposed Collection; Comment Request; Expedited Programs for Serious Conditions— Drugs and Biologics,Notice,60 Day Proposed Information Collection,2020-11-18T05:00:00Z,2020,11,2020-11-18T05:00:00Z,2021-01-20T04:59:59Z,2021-01-21T02:00:41Z,2020-25414,0,0,090000648496582e
FDA-2013-D-0575-0039,FDA,FDA-2013-D-0575,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals",Notice,Notice of Approval,2018-06-08T04:00:00Z,2018,6,2018-06-08T04:00:00Z,,2018-06-08T12:42:24Z,2018-12338,0,0,090000648337b835
FDA-2013-D-0575-0037,FDA,FDA-2013-D-0575,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Guidance for
Industry on Expedited Programs for Serious Conditions—Drugs and
Biologics",Notice,30 Day Proposed Information Collection,2018-02-07T05:00:00Z,2018,2,2018-02-07T05:00:00Z,2018-03-10T04:59:59Z,2018-03-15T01:02:49Z,2018-02415,0,0,0900006482ef68c5
FDA-2013-D-0575-0036,FDA,FDA-2013-D-0575,Agency Information Collection Activities; Proposed Collection; Comment Request; Guidance for Industry on Expedited Programs for Serious Conditions—Drugs and Biologics,Notice,60 Day Proposed Information Collection,2017-11-08T05:00:00Z,2017,11,2017-11-08T05:00:00Z,2018-01-09T04:59:59Z,2017-11-08T15:41:39Z,2017-24296,0,0,0900006482c5836f
FDA-2013-D-0575-0035,FDA,FDA-2013-D-0575,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals",Notice,Notice of Approval,2017-07-03T04:00:00Z,2017,7,2017-07-03T04:00:00Z,,2017-07-03T15:56:36Z,2017-13890,0,0,09000064827deed9
FDA-2013-D-0575-0034,FDA,FDA-2013-D-0575,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Guidance for
Industry on Expedited Programs for Serious Conditions—Drugs and
Biologics",Notice,30 Day Proposed Information Collection,2017-03-15T04:00:00Z,2017,3,2017-03-15T04:00:00Z,2017-04-15T03:59:59Z,2017-03-15T15:14:46Z,2017-05104,0,0,0900006482508722
FDA-2013-D-0575-0033,FDA,FDA-2013-D-0575,Agency Information Collection Activities: Proposed Collection; Comment Request; Guidance for Industry on Expedited Programs for Serious Conditions—Drugs and Biologics,Notice,60 Day Proposed Information Collection,2016-11-29T05:00:00Z,2016,11,2016-11-29T05:00:00Z,2017-01-31T04:59:59Z,2016-11-29T15:05:48Z,2016-28732,0,0,09000064823c5ea9
FDA-2013-D-0575-0031,FDA,FDA-2013-D-0575,"Guidance for Industry on Expedited Programs for Serious Conditions—
Drugs and Biologics; Availability",Notice,Notice of Availability,2014-05-30T04:00:00Z,2014,5,2014-05-30T04:00:00Z,,2024-11-11T20:53:08Z,2014-12534,1,0,090000648171f1ea
FDA-2013-D-0575-0032,FDA,FDA-2013-D-0575,"Guidance for Industry on Expedited Programs for Serious Conditions—
Drugs and Biologics",Other,Guidance,2014-05-30T04:00:00Z,2014,5,2014-05-30T04:00:00Z,,2021-05-06T12:58:39Z,,0,0,090000648171fab1
FDA-2013-D-0575-0030,FDA,FDA-2013-D-0575,"Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Guidance for Industry on Expedited
Programs for Serious Conditions— Drugs and Biologics",Notice,Notice of Approval,2014-05-01T04:00:00Z,2014,5,2014-05-01T04:00:00Z,,2021-02-18T18:08:39Z,2014-09914,0,0,09000064816da49d
FDA-2013-D-0575-0028,FDA,FDA-2013-D-0575,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance for Industry on Expedited Programs for Serious Conditions--Drugs and Biologics,Notice,30 Day Proposed Information Collection,2013-11-07T05:00:00Z,2013,11,2013-11-07T05:00:00Z,2013-12-10T04:59:59Z,2016-11-04T15:06:21Z,2013-26695,0,0,090000648147285f
FDA-2013-D-0575-0002,FDA,FDA-2013-D-0575,Draft Guidance for Industry on Expedited Programs for Serious Conditions--Drugs and Biologics,Other,Guidance,2013-06-26T04:00:00Z,2013,6,2013-06-26T04:00:00Z,,2024-11-12T05:18:57Z,,1,0,09000064813419e9
FDA-2013-D-0575-0001,FDA,FDA-2013-D-0575,Draft Guidance for Industry on Expedited Programs for Serious Conditions--Drugs and Biologics; Availability,Notice,Notice of Availability,2013-06-26T04:00:00Z,2013,6,2013-06-26T04:00:00Z,2013-08-27T03:59:59Z,2013-09-05T01:03:53Z,2013-15250,0,0,090000648134164a